However, it is crucial to acknowledge that treatment decisions should consider other clinical factors and further research is required to establish the role of CEA levels in making decisions regarding adjuvant therapy in patients with stage II CRC. The gene discussed is CEACAM5; the disease is colorectal carcinoma.